Jazz Pharmaceuticals
JAZZ · Pharmaceuticals
$214.00
0.3%Zoetis
ZTS · Pharmaceuticals
$81.03
1.2%The short version
- Zoetis is the larger business, with $9.5B of revenue in fiscal 2025 against $4.3B for Jazz Pharmaceuticals, about 2.2 times as much.
- Jazz Pharmaceuticals grew revenue faster (4.9%, against 2.3%).
- Jazz Pharmaceuticals turned more of its sales into free cash flow (30.4% FCF margin, against 24.1% FCF margin).
- Zoetis earned a higher return on the capital invested in it (29.3%, against −4.2%).
- Investors pay more for each dollar of Jazz Pharmaceuticals’s earnings: a P/E of 14.6x against 13.3x for Zoetis.
| Latest fiscal year | JAZZ · FY25 | ZTS · FY25 |
|---|---|---|
| Size | ||
| Market cap | $14.9B | $33.8B |
| Revenue | $4.3B | $9.5B |
| Free cash flow | $1.3B | $2.3B |
| Net income | −$356M | $2.7B |
| Growth | ||
| Revenue growth | 4.9% | 2.3% |
| 5-year growth | 12.5% | 7.2% |
| Share count change | −7.6% | −2.4% |
| Profitability | ||
| Gross margin | — | 71.8% |
| Operating margin | −10.1% | — |
| Net margin | −8.4% | 28.2% |
| FCF margin | 30.4% | 24.1% |
| Return on capital | −4.2% | 29.3% |
| Return on equity | −8.5% | 66.0% |
| Balance sheet | ||
| Net debt | $4.0B | $6.7B |
| Net debt / EBITDA | — | 1.7x |
| Dividends and buybacks | $125M | $4.1B |
| Valuation & quality | ||
| P/E | 14.6x | 13.3x |
| Piotroski F-score | 4 | 8 |
FY16
JAZZ $1.5B
ZTS $4.9B
FY17
JAZZ $1.6B
ZTS $5.3B
FY18
JAZZ $1.9B
ZTS $5.8B
FY19
JAZZ $2.2B
ZTS $6.3B
FY20
JAZZ $2.4B
ZTS $6.7B
FY21
JAZZ $3.1B
ZTS $7.8B
FY22
JAZZ $3.7B
ZTS $8.1B
FY23
JAZZ $3.8B
ZTS $8.5B
FY24
JAZZ $4.1B
ZTS $9.3B
FY25
JAZZ $4.3B
ZTS $9.5B
JAZZ
ZTS
FY16
JAZZ 39.8%
ZTS —
FY17
JAZZ 32.7%
ZTS —
FY18
JAZZ 32.5%
ZTS —
FY19
JAZZ 24.6%
ZTS —
FY20
JAZZ 16.0%
ZTS —
FY21
JAZZ 5.5%
ZTS —
FY22
JAZZ −1.8%
ZTS —
FY23
JAZZ 15.1%
ZTS —
FY24
JAZZ 17.6%
ZTS —
FY25
JAZZ −10.1%
ZTS —
JAZZ
ZTS
FY16
JAZZ $583M
ZTS $497M
FY17
JAZZ $664M
ZTS $1.1B
FY18
JAZZ $779M
ZTS $1.5B
FY19
JAZZ $736M
ZTS $1.3B
FY20
JAZZ $885M
ZTS $1.7B
FY21
JAZZ $751M
ZTS $1.7B
FY22
JAZZ $1.2B
ZTS $1.3B
FY23
JAZZ $1.1B
ZTS $1.6B
FY24
JAZZ $1.4B
ZTS $2.3B
FY25
JAZZ $1.3B
ZTS $2.3B
JAZZ
ZTS
FY16
JAZZ 16.7%
ZTS 18.5%
FY17
JAZZ —
ZTS 18.5%
FY18
JAZZ —
ZTS 26.4%
FY19
JAZZ 13.1%
ZTS 23.8%
FY20
JAZZ 7.6%
ZTS 25.0%
FY21
JAZZ 1.9%
ZTS 29.5%
FY22
JAZZ −0.6%
ZTS 27.9%
FY23
JAZZ 7.3%
ZTS 27.7%
FY24
JAZZ 9.1%
ZTS 28.3%
FY25
JAZZ −4.2%
ZTS 29.3%
JAZZ
ZTS
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.